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Abstract
Our aim was to analyze whether endotoxemia, i.e. translocation of LPS to circulation, is reflected in the serum metabolic
profile in a general population and in participants with cardiometabolic disorders. We investigated three Finnish cohorts
separately and in a meta-analysis (n¼ 7178), namely population-based FINRISK97, FinnTwin16 consisting of young adult
twins, and Parogene, a random cohort of cardiac patients. Endotoxemia was determined as serum LPS activity and
metabolome by an NMR platform. Potential effects of body mass index (BMI), smoking, metabolic syndrome (MetS), and
coronary heart disease (CHD) status were considered. Endotoxemia was directly associated with concentrations of
VLDL, IDL, LDL, and small HDL lipoproteins, VLDL particle diameter, total fatty acids (FA), glycoprotein acetyls (GlycA),
aromatic and branched-chain amino acids, and Glc, and inversely associated with concentration of large HDL, diameters
of LDL and HDL, as well as unsaturation degree of FAs. Some of these disadvantageous associations were significantly
stronger in smokers and subjects with high BMI, but did not differ between participants with different CHD status. In
participants with MetS, however, the associations of endotoxemia with FA parameters and GlycA were particularly
strong. The metabolic profile in endotoxemia appears highly adverse, involving several inflammatory characters and risk
factors for cardiometabolic disorders.
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Introduction
LPS, also known as endotoxin, is a major component
of the outer membrane of most Gram-negative bacte-
ria. Low to moderate LPS activity in serum most prob-
ably derives from microbiota colonizing the
gastrointestinal tract, including the oral cavity. LPS
originating from gut bacteria can enter the blood-
stream either by direct diffusion due to intestinal para-
cellular permeability or by being aggregated into
chylomicrons.1 Under physiological conditions, howev-
er, intestinal epithelium acts as a continuous barrier to
avoid translocation of endotoxin, and LPS activity in
serum remains low. A high-fat diet, obesity, diabetes,
and non-alcoholic fatty liver disease have been associ-
ated with increased intestinal permeability, resulting in
a two- to three-fold increase in levels of LPS in
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circulation.2 This condition, known as metabolic endo-
toxemia, associates with low-grade inflammation. In
circulation, LPS is mainly carried by lipoproteins,
most preferably high-density lipoproteins (HDL).3
HDL neutralizes LPS activity and clears LPS effective-
ly from the bloodstream.1
Circulating LPS is involved in both acute infections
and chronic conditions. It activates both innate and
adaptive immune systems, leading to the production
of Abs, cytokines and acute-phase proteins. Complete
LPS is a complex lipoglycan composed of a core oligo-
saccharide, an O-specific side chain and a lipid A
moiety, which, depending on its structure and the
host, is responsible for the biological activity of the
molecule. LPS is transferred from bacterial surfaces
or LPS aggregates to the cell surface by LPS-binding
protein, which is a positive acute-phase protein. The
pro-inflammatory cascade mediated by NF-jB is trig-
gered when LPS binds to the TLR4/CD14 complex
expressed in almost all cell types.4 Via NF-jB, LPS
also regulates metabolism by affecting gene transcrip-
tion, e.g. to activate a signaling pathway leading to
deteriorated insulin resistance.4
High LPS activity, i.e. endotoxemia, is linked to sev-
eral cardiometabolic disorders and abnormalities. LPS
activity correlates positively with serum total cholester-
ol as well as triglyceride concentrations and negatively
with HDL cholesterol concentration.5 It is related to
elevated C-reactive protein,5 insulin resistance and obe-
sity.6 Moreover, endotoxemia associates with the risk
of metabolic syndrome (MetS),5,6 predicts incident dia-
betes5 and is an independent risk factor for cardiovas-
cular diseases (CVDs).7,8
We aimed to study whether endotoxemia, defined by
the presence of LPS activity in the blood, associates
with circulating metabolites including concentrations
and compositions of lipoprotein particles, levels of
fatty acids (FAs), Aas, ketone bodies, metabolic sub-
strates, and other metabolic markers measured by
NMR spectroscopy-based methods. Besides, we ana-
lyzed whether the associations are altered in cardiome-




We investigated three Finnish cohorts: FINRISK97,
FinnTwin16 and Parogene (total n¼ 7178). All the par-
ticipants signed an informed written consent form. The
study protocols were approved by the ethics commit-
tees of Helsinki University Central Hospital and
Institute for Health and Welfare and were carried out
according to the recommendations of the 1975
Declaration of Helsinki.
The Finnish Twin Cohort Study (FinnTwin16)
FinnTwin16 is a longitudinal study consisting of 5563
Finnish mono- and dizygotic twins born in 1975–1979,
and the twins were identified through the national pop-
ulation register of Finland. The study was established
in 1991–1995 with baseline assessments of 16-yr-old
twins and their parents. The follow-up questionnaires
were conducted at ages 17, 18.5, and 23–27 yr.9 After
the fourth assessment, a sample of twin pairs concor-
dant and discordant for their alcohol use (n¼ 554 indi-
viduals) was selected for clinical examinations
including the collection of blood samples.10 The partic-
ipants were allowed to have a low-fat light breakfast,
e.g. cup of coffee, bread or fruits, before the sampling.
The Parogene Study
The original Corogene Study is based on 5295 Finnish
patients who underwent coronary angiography for any
reason at Helsinki University Central Hospital between
June 2006 and March 2008. In addition to the angio-
gram, each patient filled out a questionnaire, and infor-
mation was gathered from the medical records. The
aim of the cohort study was to investigate genetic risk
factors related to coronary artery disease.11
Approximately 10%, finally a total of 508 subjects,
were randomly selected for a complete clinical oral
examination which was performed 6 wk to 5 mo after
the angiography. These patients constitute the
Parogene Study.12 Of the Parogene Study patients,
123 (24.2%) had no significant coronary artery disease
(< 50% stenosis), 184 (36.2%) had chronic coronary
artery disease ( 50% stenosis), 169 (33.3%) had acute
coronary syndrome (defined as a chest pain caused by
myocardial ischemia and  50% stenosis), and 32
(6.3%) had acute coronary syndrome without coronary
artery disease. Non-fasting blood samples were drawn
from the patients.
The FINRISK 1997 Study (FINRISK97)
The FINRISK 1997 Study is a prospective, random
population-based survey aiming to monitor the health
of the Finnish population. In the year 1997, 8444 indi-
viduals from five separate geographical regions in
Finland were recruited to participate in clinical health
examinations including questionnaires and blood sam-
pling. The participants of the study were aged between
25 and 74. They were asked to fast for at least 4 h
before blood sampling. The median fasting time was
5 h (interquartile range 3–7 h).5 Samples from a total
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of 6159 participants were available for the present
analysis.
Some 1813 (29%) participants fulfilled the MetS
diagnostic criteria of the International Diabetes
Federation.13 Prevalent CVD covering myocardial
infarction, coronary artery disease and stroke was
defined as a self-report of doctor-diagnosed disease.
Incident CVD events were recorded during the 13-yr
follow-up time via national registers of hospitaliza-
tions, drug reimbursements and causes of death.
There were 430 (7.0%) participants who had been diag-
nosed with prevalent CVD before the establishment of
the study, and 649 (10.5%) participants were diagnosed
during the follow-up. After excluding individuals who
had experienced a stroke before the clinical survey in
1997 or during the follow-up, 365 (5.9%) and 395
(6.4%) participants remained in the groups of preva-
lent and incident CHD events, respectively.
Serum metabolomics
All cohorts were analyzed with the same high-
throughput serum NMR metabolomics platform as
described previously in detail14 by Nightingale
Health, Helsinki, Finland. There were data on 228
metabolites in FINRISK97 and Parogene and on 114
metabolites in FinnTwin16. The measures included
concentrations and compositions of lipoprotein par-
ticles as well as FAs, Aas, ketone bodies, and other
molecules involved in cell energy metabolism as well
as ratios of lipoprotein lipid subclasses and FAs. We
excluded some measures representing ratios of lipopro-
tein lipid subclasses in FINRISK97 and Parogene
cohorts, leaving 157 metabolites for analyses. The 43
variables which best described the metabolite profile
were selected for further analyses, including meta-
analyses. Six classes of different sized very-low-
density lipoprotein (VLDL) particles were re-grouped
into two variables, large and small VLDL (XXL, XL
and L VLDL as large VLDL; M, S and XS VLDL as
small VLDL). Four subclasses of HDL were similarly
re-grouped into two categories (XL and L HDL as
large HDL; M and S HDL as small HDL). Our vari-
ables “branched-chain amino acids” and “aromatic
amino acids” represent isoleucine, leucine and valine,
as well as phenylalanine and tyrosine, respectively.
Acetoacetate, acetate and b-hydroxybutyrate were
combined as one variable denoting “b-oxidation.”
Finally, these 43 metabolites comprised 11 lipoprotein,
11 lipid and eight FA-related measures, along with five
Aas and eight molecules involved in cell energy metab-
olism. Measured metabolome data were available on
554 individuals in FinnTwin16, 6159 in FINRISK97
and 465 in the Parogene Study (7178 in total).
FinnTwin16 lacked information on FA levels and
consequently the meta-analysis in this respect was
based only on the results of Parogene and
FINRISK97 (n¼ 6624).
LPS concentration measures
We analyzed serum LPS concentration by Limulus
amebocyte lysate assay (HyCult biotechnology b.v.,
Uden, the Netherlands) with a chromogenic substrate
according to the instructions provided by the manufac-
turer. The measurements were taken from distinct sam-
ples diluted (1:5 vol/vol) with endotoxin-free water.
The inter-assay coefficients of variation were 7.4%,
9.2%5 and 5.5%15 for FinnTwin16, FINRISK97 and
Parogene samples, respectively.
Statistical analyses
R (version 3.6.1 or higher, http://www.r-project.org/)
was used for all statistical analyses.
The LPS activity and metabolic measures in
FINRISK97 with highly skewed distribution
(Pearson’s moment coefficient of skewness < –1.5 or
> 1.5) were log-transformed to obtain approximately
normal distributions. Subsequently, concentrations
were scaled to a mean of zero and a standard deviation
of one. The transformations were performed similarly
for the corresponding metabolites in Parogene and
FinnTwin16. Generalized linear regression models
were fitted between LPS activity as an outcome and
metabolite concentrations as predictors for Parogene
and FINRISK97 separately. For FinnTwin16, a
linear mixed-effects model was fitted to take account
sample relatedness using family number as the random
effect of the model. The models were adjusted for age,
sex, body mass index (BMI), and current smoking
status (smoker or non-smoker). To combine the results
from individual cohorts, an inverse-variance weighted
fixed-effect meta-analysis was performed.
FINRISK97 was further analyzed after grouping
participants according to MetS, BMI, CHD status
and smoking habit. Linear regressions were calculated
for these groups separately, and to assess possible dif-
ferences, we extended the main model by interaction
terms of the grouping variables and conducted
ANOVA tests. The statistical tests were two-sided. In
addition, we acquired predictors from logistic regres-
sion of MetS and covariates including age, sex, smok-
ing, weekly alcohol intake and years of education.
Then, logistic regression models were fitted between
the predictors and five metabolites of interest with
and without LPS. To illustrate the results, receiver-
operating characteristics (ROC) curves were drawn.
Because there were strong correlations among
metabolites, a principal component (PC) analysis was
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conducted for 157 metabolic measures of FINRISK97.
Metabolites with factor loadings  –0.10 or  0.10
were considered to contribute substantially to the PC.
General linear regression models adjusted for age, sex,
BMI and current smoking were calculated between
LPS and scores of the 22 first PCs.
Results
We analyzed the associations between LPS and circu-
lating metabolites in three Finnish cohorts comprising
altogether 7178 individuals. The characteristics of the
cohorts are summarized in Table 1. The FINRISK97
study is population based (49% women and a mean age
of 50 yr), Parogene consists of patients who underwent
coronary angiography (31% women and a mean age of
64 yr) and FinnTwin16 is composed of young adult
twins (49% women and a mean age of 26 yr).
We conducted a PC analysis for 157 metabolites
measured from FINRISK97. The first 22 PCs
explained more than 95% of the variation of the data
(Supplemental Table 1). Thus, the P value threshold
for statistical significance was set to 0.05/22¼ 0.0023
in further analyses.
We included altogether 157 serum metabolites in our
linear regression models of the separate cohorts and 43
metabolites in the meta-analysis combining the results.
The mean values and standard deviations of the metab-
olite measures in the different study cohorts are pre-
sented in Supplemental Table 2. Supplemental Figure 1
shows LPS distributions in each cohort. According to
the meta-analysis, all 43 metabolites were significantly
associated with endotoxemia (P< 0.0023), and these
results are shown in Figures 1–3 and Supplemental
Figure 2.
Principal component analysis
We studied the associations between endotoxemia and
the first 22 PCs acquired from the metabolite measures







for coronary angiography Young adult twins
n 6,159 465 554
Women (%) 3,027 (49.1) 163 (35.1) 273 (49.3)
Mean age, yr 53.0 (10.6) 63.6 (9.0) 26.2 (1.4)
Current smokers (%) 1,376 (22.3 ) 55 (11.8) 229 (41.3)
Mean BMI, kg/m2 27.2 (4.5) 27.8 (5.0) 23.9 (4.0)
Underweight, <18.50 (%) 29 (0.5) 5 (1.1) 12 (2.2)
Normal weight, 18.50–24.99 (%) 2,025 (32.9) 134 (28.8) 351 (63.4)
Overweight, 25.00–29.99 (%) 2,718 (44.1) 200 (43.0) 128 (23.1)
Obese,  30.00 (%) 1,376 (22.3) 122 (26.2) 34 (6.14)
Diabetes mellitus (%) 438 (7.1) 108 (23.2) 0 (0)
Lipid-lowering medication (%) 269 (4.4) 370 (79.6) 0 (0)
Mean LPS concentration, EU/ml 0.63 (0.37) 0.63 (0.44) 0.67 (0.23)
Total cholesterol, mmol/l* 5.47 (1.07) 3.28 (0.82) 4.98 (0.89)
LDL cholesterol, mmol/l* 2.00 (0.58) 1.10 (0.44) 1.87 (0.52)
HDL cholesterol, mmol/l* 1.57 (0.39) 1.20 (0.33) 1.77 (0.42)
Total triglycerides, mmol/l* 1.38 (0.70) 1.25 (0.62) 1.30 (0.60)
Numbers indicate n (%) or mean (standard deviation) when appropriate. *Concentrations acquired by NMR.
Figure 1. Factor loadings and scores of the first two principal
components in FINRISK97. The loadings of the designated
metabolites are shown. FAs represent their ratios to total FA
concentration. The figure also illustrates the scores of subjects
belonging to the highest and lowest deciles by their LPS values.
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in FINRISK97 (Supplemental Table 1). The first three
PCs associated directly with endotoxemia. PC1 had
positive factor loadings of VLDL parameters, apoB,
and FAs including monounsaturated (MUFA) and sat-
urated (SAFA) fatty acids (Figure 1), whereas PC2 was
characterized by a large mean diameter of VLDL, low
HDL and low-density lipoprotein (LDL) cholesterol
contents, in addition to small HDL particle size. PC3
comprised high levels of lipid-rich HDL particles and
FAs together with MUFA and SAFA, as well as a low
ratio of apolipoprotein B (apoB) to apolipoprotein A1
(apoA1).
Lipoprotein associations with endotoxemia
The associations of LPS activity with concentrations
and mean diameters of lipoprotein particles are
shown in Figures 2a and 2b. Endotoxemia was posi-
tively associated with concentrations of chylomicrons
and VLDL, as well as intermediate-density lipoprotein
(IDL) and LDL particles in the meta-analysis.
Endotoxemia was inversely associated with the
concentrations of large HDL particles, whereas there
was a direct association with concentration of small
HDL particles. A weak association was also observed
between endotoxemia and total HDL concentration in
FINRISK97 (b¼ 0.02, 95% confidence interval (CI)
0.01, 0.04, P¼ 0.0006), but in other cohorts or in the
meta-analysis this association was not significant
(P¼ 0.007). Among the particle sizes, endotoxemia
was directly associated with VLDL diameter, while
the associations with the diameters of LDL and HDL
were inverse.
The associations between endotoxemia and apolipo-
proteins are presented in Supplemental Figure 2.
A small but statistically significant association with
endotoxemia was observed for apoA1, whereas the
associations for apoB and apoB/apoA1-ratio were con-
siderably stronger. The figure also illustrates the asso-
ciations between endotoxemia and total lipids in
lipoprotein particles. Positive associations were found
with total lipids of VLDL and IDL, as well as LDL.
Among the total lipids in HDL particles, there was an
Figure 2. The associations of endotoxemia with (a) concentrations of VLDL, IDL and LDL, and (b) concentrations of HDL particles
and diameters of lipoprotein particles. The b-values and 95% confidence intervals from the analyses of the individual cohorts and from
inverse-variance weighted fixed-effect meta-analysis are presented. The linear regression models were adjusted for age, sex, BMI, and
current smoking status, as well as kinship in FinnTwin16. Metabolites labeled with “log” were log-transformed to obtain normal
distributions.
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inverse association with large HDL, and a direct asso-
ciation with small HDL particles. The associations of
endotoxemia with all the measured metabolites includ-
ing exact lipoprotein lipid subclasses in separate
cohorts are presented in Supplemental Table 3.
Endotoxemia and fatty acids
Total FAs and all the other measured absolute levels
of FAs associated directly with endotoxemia
(Supplemental Table 2). However, as shown in Figure
3, among relative concentrations of FAs, we observed
more heterogeneity: unsaturation degree of FAs, pro-
portions of polyunsaturated fatty acids (PUFA),
including omega-3 FAs, docosahexaenoic acid
(DHA), and omega-6 FAs, including linoleic acid
were inversely associated with endotoxemia, whereas
endotoxemia was directly associated with proportions
of MUFA and SAFA.
Other molecules
Aromatic Aas, phenylalanine and tyrosine, were posi-
tively associated with endotoxemia (Figures 4a and
4b). Among Aas, however, the strongest associations
were found for branched-chain Aas, isoleucine, leucine
and valine. In addition, we observed positive associations
of endotoxemia with alanine and histidine, and inverse
association with glutamine. Among glycolysis- and
gluconeogenesis-related metabolites, Glc was positively
associated with endotoxemia, along with lactate,
pyruvate and glycerol, while only citrate was negatively
associated with LPS. Acetoacetate, acetate and
b-hydroxybutyrate originating from b-oxidation were
directly associated with endotoxemia. There were also
positive associations for albumin, creatinine, and GlycA.
Endotoxemia and MetS
Next, we analyzed whether the associations between
endotoxemia and the metabolites differ between sub-
jects with and without MetS in FINRISK97 (Figure 5).
We detected a significantly stronger positive associa-
tion of endotoxemia with concentrations and total
lipid contents of large VLDL and IDL, as well as
VLDL diameter among subjects with MetS compared
with those without. Similarly, the participants with
MetS had a significantly stronger positive association
between endotoxemia and relative levels of omega-3
FAs, DHA, PUFA, MUFA, and SAFA, as well as
unsaturation degree of FAs. The effect of endotoxemia
on the relationships between MetS and five metabolites
of interest was analyzed further. LPS (OR, 95% CI;
2.00, 1.87–2.13), MUFA (3.26, 3.02–3.53), PUFA
(0.33, 0.31–0.35), SAFA (1.47, 1.39–1.56), unsaturation
degree (0.48, 0.45–0.51) and GlycA (3.82, 3.52–4.15)
were all strongly associated with MetS. The discrimina-
tion ability of the models with and without LPS were
compared with C-statistics, and the area under curve
(AUC) values (Supplemental Table 4) and ROC
curves are presented (Figure 6). LPS alone provided
an AUC of 0.686 (0.671–0.701) to differentiate partici-
pants with and without MetS. Including any of the five
metabolites in the model increased its discrimination
ability significantly (Supplemental Table 4). Adding
LPS in the models with unsaturation degree of FAs or
proportion of SAFA clearly improved the AUCs. The
best discrimination, however, was achieved with LPS
and GlycA providing an AUC of 0.819 (0.807–0.831).
Endotoxemia and CHD status, smoking and BMI
We also analyzed whether the associations between
endotoxemia and the metabolites differ between sub-
jects with varying CHD status, current smokers and
Figure 3. The associations of endotoxemia with fatty acids. The
b-values and 95% confidence intervals from the analyses of the
individual cohorts and from inverse-variance weighted fixed-
effect meta-analysis are presented. The linear regression models
were adjusted for age, sex, BMI, and current smoking status.
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non-smokers, and BMI categories. These results are
presented in Supplemental Figures 3–5.
The CHD status, i.e. no CHD, prevalent CHD, and
incident CHD, affected significantly only the associa-
tions of endotoxemia with concentrations of large
VLDL particles and their total lipids. Compared with
non-smokers, the current smokers presented a stronger
association of endotoxemia with LDL diameter, pro-
portion of linoleic acid, and glycerol. Among BMI cat-
egories, i.e. underweight or normal weight, overweight,
and obese, significant differences were found in associ-
ations of endotoxemia with large VLDL particles and
their lipid content, IDL lipid content, albumin, and
omega-3 FAs.
Discussion
In our large study conducted among over 7000 partic-
ipants, we showed that endotoxemia is associated with
high concentrations of VLDL, IDL and LDL particles,
and low concentrations of HDL particles. It is also
associated with large VLDL, but small LDL and
HDL particle diameters. In addition, there was a
direct association between endotoxemia and FAs with
a high saturation degree. Also notable was the positive
association of endotoxemia with aromatic and
branched-chain Aas, as well as GlycA, and Glc.
Some of these disadvantageous associations were sig-
nificantly stronger in smokers and subjects with high
BMI, but especially in participants with MetS. The
metabolic profile in endotoxemia appears highly
adverse, involving several inflammatory characters
and risk factors for cardiometabolic disorders.
The process of lipoprotein remodeling is a major
manifestation of aberrant metabolic pathway utiliza-
tion occurring in inflammatory diseases.16 These
changes in lipoprotein composition affect both the
host immune response (due to different LPS
Figure 4. The associations of endotoxemia with (a) Aas, and (b) metabolic substrates, ketone bodies and other metabolic markers.
The b-values and 95% confidence intervals from the analyses of the individual cohorts and from inverse-variance weighted fixed-effect
meta-analysis are presented. The linear regression models were adjusted for age, sex, BMI, and current smoking status. Metabolites
labeled with “log” were log-transformed to obtain normal distributions.
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inactivation efficacy of different lipoprotein classes)
and the host metabolic phenotype. In terms of metab-
olism, this is substantiated by findings that LPS induces
adipose tissue lipolysis, providing an increased supply
of free FAs that are subject to hepatic uptake. In the
liver, decreased b-oxidation together with increased FA
synthesis results in increased hepatic de novo
lipogenesis. Increased VLDL synthesis and secretion
is observed as the net effect of overshooting hepatic
triglyceride synthesis.17 A decrease in lipoprotein
lipase activity leads to delayed clearance and
prolonged circulation of triglyceride-rich lipoproteins
during inflammatory conditions. In line, the present
study revealed a positive association of metabolic
endotoxemia with concentrations, total lipid content,
and mean diameter of VLDL particles.
Krauss described two distinct LDL phenotypes, (i)
the predominance of large buoyant (lb)LDL particles
(phenotype A) and (ii) conditions where small dense
(sd)LDL particles (phenotype B) predominate.18
Results obtained during the present study indicated
the preponderance of sdLDL particles in metabolic
endotoxemia. Whether sdLDL are produced from
triglyceride-rich VLDL or lbLDL is not entirely clear
and depends on the underlying metabolic condition.19
These sdLDL particles have a low affinity to the LDL
receptor, enter the arterial wall and are highly suscep-
tible to oxidative modifications leading to enhanced
uptake by macrophages,20 a process ultimately giving
rise to subendothelial foam cell formation.
Peripheral inflammation also impacts HDL struc-
ture and function through alterations in the lipid and
protein moieties. These changes affect anti-
inflammatory, anti-oxidative and reverse cholesterol
transport properties of HDL particles.21 Here, we
found a negative association between endotoxemia
and the mean diameter of HDL particles. There was
a slightly positive association for apoA1, the most
prominent protein in HDL, but no association between
endotoxemia and total HDL concentration. Thus, our
findings concerning HDL do not exactly meet the char-
acteristics of acute-phase HDL. During the acute-phase
response, the concentration of HDL decreases, while
the particle undergoes phospholipid transfer protein-
mediated conversion,22 and apoA1 is replaced by
serum amyloid A.23 These alterations are seen in
inflammatory diseases such as rheumatoid arthritis,
MetS and atherosclerosis, as well as infections.20
Many of these diseases are also associated with a
higher risk for CVD.20 Large and medium-sized HDL
Figure 5. The associations between LPS and metabolites in subjects with and without metabolic syndrome (MetS) in FINRISK97. The
subjects of FINRISK97 were grouped according to the MetS status. General linear regression models adjusted for age, sex, BMI, and
current smoking status were fitted between LPS and the metabolites in each group. The significance of the differences in the
regressions between the groups was analyzed by adding an interaction term of the MetS status with metabolite concentration in the
main model and conducting ANOVA. The b-values and 95% confidence intervals are presented. Metabolites labeled with “log” were
log-transformed to obtain normal distributions. *: P< 0.0023 (ANOVA).
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are more effective in reverse cholesterol transport than
small HDL.24 In our study, high endotoxemia was
associated with concentrations of small HDL, whereas
large HDL particles associated with lower endotoxe-
mia. It is reasonable to assume that this dysfunctional
HDL profile probably predicts poor cholesterol efflux
capacity.
Diabetic dyslipidemia is a condition interrelated
with insulin resistance and type 2 diabetes mellitus
(T2DM). This disorder is characterized by hepatic
overproduction of large, triglyceride-rich VLDL.25
Highly atherogenic sdLDL is another feature of lipo-
protein profile observed in diabetic dyslipidemia.25
These alterations in the lipoprotein profile of subjects
with MetS may explain the differences we observed
here between the groups. We showed that endotoxemia
associated more strongly with concentrations and lipid
contents of the larger VLDL population among partic-
ipants with MetS compared with those without. VLDL
diameter was also more strongly associated with endo-
toxemia in MetS. In addition, in this group, we found
that the negative association between endotoxemia and
Figure 6. ROC curves with MetS as a response and metabolites and LPS as predictors in FINRISK97. We acquired the predictors
from logistic regression of MetS and covariates including age, sex, smoking, weekly alcohol intake and years of education. Then, logistic
regression models were fitted between the predictors and the metabolites of interest with and without LPS. AUC-values for
metabolites are presented. P-values depict the discrimination ability of the models with and without LPS. PUFA, polyunsaturated fatty
acids; MUFA, monounsaturated fatty acids; SAFA, saturated fatty acids; UNSAT, unsaturation degree of fatty acids; GlycA, glycoprotein
acetyls.
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LDL diameter was more remarkable, emphasizing the
abundance of small, dense LDL in MetS.26
As mentioned above, changes in the compositions
and concentrations of plasma lipids affect the host
immune response due to LPS binding by lipoproteins.
Lipoproteins are generally considered as protective
during LPS-mediated inflammation, as the majority
of LPS is bound to circulating lipoproteins.3 HDL
appears to inactivate LPS with highest efficacy, where-
as lipoproteins with lower densities are less efficient in
neutralizing its function.27 In contrast to physiological
conditions, LDL or VLDL particles are the major LPS
carriers in patients with sepsis.27 LPS redistribution
between different lipoprotein classes is dependent on
LPS-binding protein and phospholipid transfer pro-
tein,28 a lipid transfer enzyme and major effector of
lipoprotein particle size.22 Of note, we have previously
demonstrated that the specific activity of phospholipid
transfer protein is significantly up-regulated in severe
acute-phase response patients.22 As we observed a pos-
itive relationship between endotoxemia and small HDL
diameter but no association for total HDL concentra-
tion, our findings suggest that HDL subclasses of dif-
ferent sizes vary in their capability of neutralizing LPS.
Findings obtained during the present serum NMR
metabolomics study indicate substantial association
between endotoxemia and a number of metabolites fre-
quently associated with MetS or T2DM.29
Endotoxemia can induce insulin resistance that is,
among other features, characterized by reduced Glc
utilization in adipose tissue and skeletal muscle, result-
ing in increased adipose tissue lipolysis, skeletal muscle
proteolysis, and hepatic gluconeogenesis to compensate
for energy deficits.
During the present study, we observed a positive
association of endotoxemia with concentrations and
several markers of FA composition and saturation in
both the FINRISK97 and Parogene cohorts. These
findings would be compatible with increased adipose
tissue lipolysis resulting from limited GLUT4-
mediated Glc availability as observed in MetS and
insulin resistance. When the subjects of the
FINRISK97 study were grouped according to the
MetS status, PUFA, omega-3 and DHA levels (all neg-
atively associated with endotoxemia) were significantly
different in the MetS group. In contrast, the positive
associations with MUFA and SAFA were significantly
higher in the MetS population. Whether this is a result
of aberrant redox control experienced by patients with
MetS30 and thus consumption of highly unsaturated
FAs due to higher oxidative stress conditions, remains
to be elucidated. Also, the reasons for the negative
association with ketone bodies acetate, acetoacetate
and b-hydroxybutyrate, which are synthesized from
FA-derived acetyl-coenzyme A, are currently unclear.
In the Aa cluster, several metabolites considered as
biomarkers in the setting of poor glycemic control were
associated with endotoxemia in the present study:
branched-chain Aas valine, leucine and isoleucine as
well as alanine and histidine were positively associated,
whereas glutamine showed negative association with
endotoxemia. The branched-chain Aas were previously
shown to be associated with insulin resistance and dia-
betes risk.31,32 Mechanistically it was suggested that
branched-chain Aas together with lipoprotein-derived
lipids affect the responsiveness of peripheral tissues to
insulin, as branched-chain Aa-induced insulin resis-
tance in rodents occurs only on the background of a
high-fat diet.29,33 The high concentrations of
triglyceride-rich VLDL particles observed here would
be compatible with such a concept.
GlycA derive from glycan N-acetylglucosamine res-
idues on enzymatically glycosylated acute-phase pro-
teins, mainly a1-acid glycoprotein but also
haptoglobin, a1-antichymotrypsin, and transferrin.
34
It is a systemic inflammation marker and a predictor
of several incident diseases including T2DM35 and
CVD.36 In our study, LPS was strongly associated
with GlycA, and the association was especially promi-
nent in participants suffering from MetS. Both LPS
and GlycA have been earlier shown to have a positive
association with insulin resistance, serum insulin, tri-
glycerides, total and LDL-cholesterol, and a negative
association with insulin sensitivity even in young, over-
weight women,37 emphasizing their role as both medi-
ators and biomarkers of inflammation in metabolic
disorders.
There are some limitations concerning our study.
Most of the metabolites were highly correlated with
each other, which contributed to a substantial
number of statistically significant results, despite
Bonferroni correction based on PCs. Limulus amebo-
cyte lysate assay, which was used in measuring LPS
levels from serum samples, has also drawn some criti-
cism.38 In addition, as the study is cross-sectional in
nature, no conclusions regarding causal relationships
between LPS and metabolite levels can be drawn. The
fasting time before sampling differed between the
cohorts. In the largest cohort, the FINRISK97, how-
ever, the fasting time had only a weak correlation with
LPS activity.5 The strengths of our study include a rel-
atively large sample size and diverse cohorts represent-
ing the whole population from young, healthy adults to
the elderly with cardiac problems. Furthermore, our
results were highly consistent in the three cohorts.
We showed that endotoxemia associated with lipo-
protein profile reflecting many inflammatory features
and risk factors for CVD: high VLDL concentration
with large particle size and unaltered HDL concentra-
tion with small particle size. According to our study,
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endotoxemia was also associated with saturated FAs,
which can act as inflammatory triggers, and GlycA,
which are inflammation markers and predictors of sev-
eral incident diseases and mortality. In conclusion, our
findings indicate a strong association of endotoxemia
with an adverse metabolic profile linked to cardiome-
tabolic disorders. Thus, serum LPS activity might pro-
vide information on the conceivable metabolic profile
and the risk of developing these diseases.
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14. Soininen P, Kangas AJ, Würtz P, et al. High-throughput
serum NMR metabolomics for cost-effective holistic
studies on systemic metabolism. Analyst 2009; 134: 1781.
15. Liljestrand JM, M€antyl€a P, Paju S, et al. Association of
endodontic lesions with coronary artery disease. J Dent
Res 2016; 95: 1358–1365.
16. Feingold KR and Grunfeld C. The effect of
inflammation and infection on lipids and lipoproteins,
M€a€att€a et al. 13
https://www.endotext.org/chapter/the-effect-of-inflamma
tion-and-infection-on-lipids-and-lipoproteins/ (2019,
accessed 16 June 2019).
17. Sparks J, Sparks C and Adeli K. Selective hepatic
insulin resistance, VLDL overproduction, and hypertri-
glyceridemia. Arterioscler Thromb Vasc Biol 2012; 32:
2104–2112.
18. Krauss RM. Low-density lipoprotein subclasses and risk
of coronary artery disease. Curr Opin Lipidol 1991; 2:
248–252.
19. Diffenderfer MR and Schaefer EJ. The composition and
metabolism of large and small LDL. Curr Opin Lipidol
2014; 25: 221–226.
20. Khovidhunkit W, Kim M-S, Memon RA, et al. Effects of
infection and inflammation on lipid and lipoprotein
metabolism: mechanisms and consequences to the host.
J Lipid Res 2004; 45: 1169.
21. Rosenson RS, Bryan HB Jr, Ansell BJ, et al.
Dysfunctional HDL and atherosclerotic cardiovascular
disease. Nat Rev Cardiol 2016; 13: 48–60.
22. Pussinen PJ, Metso J, Malle E, et al. The role of plasma
phospholipid transfer protein (PLTP) in HDL remodel-
ing in acute-phase patients. Biochim Biophys Acta 2001;
1533: 153–163.
23. Coetzee GA, Strachan AF, van der Westhuyzen DR,
et al. Serum amyloid A-containing human high-density
lipoprotein 3. Density, size, and apolipoprotein compo-
sition. J Biol Chem 1986; 261: 9644.
24. Mutharasan RK, Thaxton CS, Berry J, et al. HDL efflux
capacity, HDL particle size, and high-risk carotid athero-
sclerosis in a cohort of asymptomatic older adults: The
Chicago Healthy Aging Study. J Lipid Res 2017; 58:
600–606.
25. Taskinen MR. Diabetic dyslipidaemia: from basic
research to clinical practice. Diabetologia 2003; 46:
733–749.
26. Actis Dato V and Chiabrando GA. The role of low-
density lipoprotein receptor-related protein 1 in lipid
metabolism, Glc homeostasis and inflammation. Int J
Mol Sci 2018; 19: 1780.
27. Levels JHM, Lemaire LCJM, van den Ende AE, et al.
Lipid composition and lipopolysaccharide binding capac-
ity of lipoproteins in plasma and lymph of patients with
systemic inflammatory response syndrome and multiple
organ failure. Crit Care Med 2003; 31: 1647–1653.
28. Levels JHM, Marquart JA, Abraham PR, et al.
Lipopolysaccharide is transferred from high-density to
low-density lipoproteins by lipopolysaccharide-binding
protein and phospholipid transfer protein. Infect Immun
2005; 73: 2321–2326.
29. ‘t Hart LM, Vogelzangs N, Mook-Kanamori DO, et al.
Blood metabolomic measures associate with present and
future glycemic control in type 2 diabetes. J Clin
Endocrinol Metab 2018; 103: 4569–4579.
30. Carrier A. Metabolic syndrome and oxidative stress: A
complex relationship. Antioxid Redox Signal 2017; 26:
429–431.
31. Lotta LA, Scott RA, Sharp SJ, et al. Genetic predisposi-
tion to an impaired metabolism of the branched-chain
amino acids and risk of type 2 diabetes: A Mendelian
randomisation analysis. PLoS Med 2016; 13: e1002179.
32. Lent-Schochet D, McLaughlin M, Ramakrishnan N,
et al. Exploratory metabolomics of metabolic syndrome:
A status report. World J Diabetes 2019; 10: 23–36.
33. Newgard CB. Interplay between lipids and branched-
chain amino acids in development of insulin resistance.
Cell Metab 2012; 15: 606–614.
34. Otvos JD, Shalaurova I, Wolak-Dinsmore J, et al.
GlycA: A composite nuclear magnetic resonance bio-
marker of systemic inflammation. Clin Chem 2015; 61:
714–723.
35. Akinkuolie A, Pradhan A, Buring J, et al. Novel protein
glycan side-chain biomarker and risk of incident type 2
diabetes mellitus. Arterioscler Thromb Vasc Biol 2015; 35:
1544–1550.
36. Akinkuolie AO, Buring JE, Ridker PM, et al. A novel
protein glycan biomarker and future cardiovascular dis-
ease events. J Am Heart Assoc 2014; 3: e001221.
37. Mokkala K, Pellonper€a O, R€oyti€o H, et al. Increased
intestinal permeability, measured by serum zonulin, is
associated with metabolic risk markers in overweight
pregnant women. Metabolism 2017; 69: 43–50.
38. Novitsky TJ. Limitations of the Limulus amebocyte
lysate test in demonstrating circulating lipopolysacchar-
ides. Ann N Y Acad Sci 1998; 851: 416–421.
14 Innate Immunity 27(1)
